ImmuPharma plc (LON:IMM – Get Free Report)’s stock price fell 9.4% during mid-day trading on Wednesday. The company traded as low as GBX 3.70 and last traded at GBX 3.71. 6,693,244 shares changed hands during trading, an increase of 168% from the average daily volume of 2,495,210 shares. The stock had previously closed at GBX 4.10.
ImmuPharma Price Performance
The firm has a market cap of £24.27 million, a price-to-earnings ratio of -4.68 and a beta of 3.02. The stock has a 50-day moving average of GBX 3.63 and a 200-day moving average of GBX 4.04.
ImmuPharma (LON:IMM – Get Free Report) last posted its quarterly earnings data on Tuesday, September 15th. The company reported GBX (0.84) EPS for the quarter. ImmuPharma had a negative return on equity of 559.87% and a net margin of 3,519.56%. On average, equities analysts expect that ImmuPharma plc will post -339.00 EPS for the current fiscal year.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
See Also
- Five stocks we like better than ImmuPharma
- NextEra and Dominion Have a Deal—Now Comes the Hard Part
- Microsoft’s Earnings Problem: Even Great May Not Be Enough
- 3 Stocks With Yields Big Enough to Make Election Volatility Easier to Stomach
- Is Texas Instruments Setting Up for Its Next Big Breakout?
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
